| Literature DB >> 7001645 |
S B Leapman, J B Rosenberg, R S Filo, E J Smith.
Abstract
The pharmacodynamics of thiabendazole (TBZ) and its metabolite, 5OH-thiabendazole (5OH-TBZ), were studied in an anephric patient with Strongyloides stercoralis pneumonitis. No toxic manifestations were noted in the patient, and serum TBZ and 5OH-TBZ levels were comparable to those in eunephric patients. We conclude that thiabendazole, in the usual recommended dose of 25 mg/kg twice daily, given to patients with compromised renal function is reasonable and safe.Entities:
Mesh：
Substances：
Year: 1980 PMID： 7001645 DOI： 10.1097/00007611-198010000-00034
Source DB: PubMed Journal: South Med J ISSN： 0038-4348 Impact factor: 0.954